Company Product Description Indication Status
Phase I
Asana Biosciences LLC, of Lawrenceville, N.J. ASN-008 Topical sodium ion channel blocker Pruritus Single application achieved a clinically meaningful reduction in pruritus of ≥ 4 points on the NRS in 2-3 hours
Inmed Pharmaceuticals Inc., of Vancouver, British Columbia INM-755 Cannabinol cream Epidermolysis bullosa and potentially other dermatological diseases Completed enrollment in study of healthy subjects; results expected in second half of 2020
Innate Pharma SA, of Marseille, France IPH-5201 Anti-CD39 monoclonal antibody Solid tumor First patient dosed in trial evaluating monotherapy and combination with durvalumab with or without oleclumab
Medivir AB, of Stockholm MIV-818 Prodrug of troxacitabine Liver tumor First patient dosed in phase Ib study, seeking to establish safety and tolerability profile while exploring efficacy
Phase II
Acceleron Pharma Inc., of Cambridge, Mass. ACE-083 GDF-8 antagonist  Charcot-Marie-Tooth disease Did not achieve statistically significant improvements in functional endpoints vs. placebo; development discontinued
Albireo Pharma Inc., of Boston Elobixibat  Ileal bile acid transporter inhibitor Nonalcoholic steatohepatitis/fatty liver disease Achieved full patient enrollment; on track to report top-line data mid-2020
Asana Biosciences LLC, of Lawrenceville, N.J. Gusacitinib Dual SYK/JAK kinase inhibitor Atopic dermatitis Achieved primary endpoint of a statistically significant reduction in the Eczema Area and Severity Index score at the 60-mg and 80-mg doses vs. placebo at week 12
Santen Pharmaceutical Co. Ltd., of Osaka, Japan, and Tracon Pharmaceuticals Inc., of San Diego DE-122 (carotuximab) Endoglin inhibitor  Wet age-related macular degeneration Discontinued development in wet AMD after top-line data indicated DE-122 did not improve visual acuity when combined with Lucentis (ranibizumab) as compared to single-agent Lucentis treatment
Phase III
Gilead Sciences Inc., of Foster City, Calif. Descovy (emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets Antiretroviral therapy HIV pre-exposure prophylaxis  Longer-term results from Discovery trial for PrEP use showed continued noninferior efficacy and continued favorable changes in key markers of renal and bone safety at week 96 vs. Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg); those results were achieved in the overall study population of men and transgender women at risk for HIV infection, as well as in study subpopulations of participants 50 and older, those younger than 25, and those with moderate renal impairment
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan Ninlaro (ixazomib) Oral proteasome inhibitor Multiple myeloma Addition of ixazomib to lenalidomide and dexamethasone in Tourmaline-MM2 trial resulted in an improvement in median progression-free survival of 13.5 months (p=0.073); but did not meet the threshold for statistical significance


For more information about individual companies and/or products, see Cortellis.

No Comments